Commentary Open Access
Volume 2 | Issue 1 | DOI: https://doi.org/10.46439/immunol.2.016
FXYD3-IL-17 positive feedback loop promotes psoriasis exacerbation
Meng Xia1,*, Qingqing Wang1,2,*
- 1Institute of Immunology, Zhejiang University School of Medicine, 310058 Hangzhou, China
- 2Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, 311121 Hangzhou, China
Corresponding Author
Meng Xia, xiameng.dream@zju.edu.cn; Qingqing Wang, wqq@zju.edu.cn
Received Date: April 27, 2023
Accepted Date: May 13, 2023
Xia M, Wang Q. FXYD3-IL-17 positive feedback loop promotes psoriasis exacerbation. J Cell Mol Immunol. 2023;2(1):16-18.
Copyright: © 2023 Xia M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Stem cell secretome-mediated alleviation of scalp psoriasis: A case report
Scalp psoriasis, a skin condition characterized by red, thickened (erythematous), well-demarcated patches or plaques with overlying silvery-white scales, affecting part or all of the scalp, is an autoimmune disease accompanied by itchy skin. The disease is associated with faulty functioning of adaptive and innate components of immune systems. The key pro- inflammatory cytokines mediating immunopathology of psoriasis are IL-17 and IL-23 which promote proliferation of Th 17 cells which in turn induce proliferation of keratinocytes leading to the disease.
Commentary on “Identification of CD19 as a shared biomarker via PPARγ/β-catenin/Wnt3a pathway linking psoriasis and major depressive disorder”
This study presents a comprehensive exploration into the shared molecular mechanisms linking psoriasis and major depressive disorder (MDD), two conditions that are increasingly recognized as having potential comorbidities. It offers new insights into the immune and genetic pathways that may contribute to both disorders, emphasizing the potential of CD19 as a biomarker and therapeutic target through the PPARγ/β-catenin/Wnt3a signaling pathway.
FXYD3-IL-17 positive feedback loop promotes psoriasis exacerbation
Psoriasis is primarily a chronic skin disease characterized by keratinocyte hyperplasia, as well as a systemic inflammatory disease associated with numerous comorbidities, including rheumatological psoriatic arthritis, cardiovascular and psychiatric complications. Approximately 2-3% of the global population is affected by psoriasis, and despite advances in the treatment, there are still limitations.
An analysis of racial disparities in systemic treatments for psoriasis and their pharmacologic consequences
Psoriasis is a systemic inflammatory skin disease associated with significant comorbidities, yet access to effective systemic treatments remains disparate across racial and ethnic groups. Building upon recent findings of disparities in systemic medication prescriptions and hospitalization outcomes among patients with psoriasis, this commentary explores the pharmacologic, toxicologic, and health equity implications of these inequities.